Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

In myelofibrosis (MF), driver mutations in JAK2, MPL, or CALR impact survival and progression to blast phase, with the greatest risk conferred by triple-negative status. Subclonal mutations, including mutations in high–molecular risk (HMR) genes, such as ASXL1, EZH2, IDH1/2, and SRSF2 have also been...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Blood Adv
Κύριοι συγγραφείς: Spiegel, Jay Y., McNamara, Caroline, Kennedy, James A., Panzarella, Tony, Arruda, Andrea, Stockley, Tracy, Sukhai, Mahadeo, Thomas, Mariam, Bartoszko, Justyna, Ho, Jenny, Siddiq, Nancy, Maze, Dawn, Schimmer, Aaron, Schuh, Andre, Sibai, Hassan, Yee, Karen, Claudio, Jamie, Devlin, Rebecca, Minden, Mark D., Kamel-Reid, Suzanne, Gupta, Vikas
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2017
Θέματα:
Myeloid Neoplasia
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728340/
https://ncbi.nlm.nih.gov/pubmed/29296819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017009530
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια